CTA
HAE icon

Carillon Tower Advisers’s Haemonetics HAE Stock Holding History

Carillon Tower Advisers’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-344,772
Closed -$31.6M – 471
2020
Q1 		$31.6M Hold
344,772
– – 0.31% 117
2019
Q4 		$39.6M Sell
344,772
-79,361
-19% -$9.6M 0.26% 134
2019
Q3 		$53.5M Hold
424,133
– – 0.37% 82
2019
Q2 		$51M Hold
424,133
– – 0.35% 95
2019
Q1 		$37.1M Hold
424,133
– – 0.26% 144
2018
Q4 		$42.4M Hold
424,133
– – 0.36% 88
2018
Q3 		$48.6M Buy
+424,133
New +$43.9M 0.35% 99

Other funds holding HAE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Carillon Tower Advisers's HAE Position: Q2 2020 in Review

Carillon Tower Advisers sold out of Haemonetics (HAE) in Q2 2020, closing a stake of 344,772 shares — an estimated $31.6M sold.

Carillon Tower Advisers first reported a position in HAE in Q3 2018 and held it in 7 quarters. The position peaked at $53.5M in Q3 2019. 285 funds tracked by Wall St. Rank hold HAE as of Q2 2020.

  • Carillon Tower Advisers reported no remaining Haemonetics position as of Q2 2020 after selling out during the quarter.
  • Carillon Tower Advisers sold 344,772 Haemonetics shares in Q2 2020, an estimated $31.6M.
  • Carillon Tower Advisers first reported a position in Haemonetics in Q3 2018 and held it in 7 quarters.
  • Carillon Tower Advisers's Haemonetics position peaked at $53.5M in Q3 2019.
  • 285 funds tracked by Wall St. Rank held Haemonetics as of Q2 2020.

Based on Carillon Tower Advisers's 13F filing for Q2 2020, filed 12 Aug 2020.